Achillion Pharmaceuticals Inc (ACHN)

4.11
NASDAQ : Health Care
Prev Close 4.10
Day Low/High 4.00 / 4.16
52 Wk Low/High 3.15 / 9.19
Avg Volume 1.94M
Exchange NASDAQ
Shares Outstanding 136.76M
Market Cap 560.72M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dow, S&P 500 on Track for Best Day in 6 Months as Irma Worries Ease

Dow, S&P 500 on Track for Best Day in 6 Months as Irma Worries Ease

The Dow is up more than 250 points.

Dow Trades Above 22,000 as Irma's Damage Estimates Lower Than Feared

Dow Trades Above 22,000 as Irma's Damage Estimates Lower Than Feared

Wall Street moves higher.

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

The New Haven, Conn.-based firm on Sept. 9 received a termination notice regarding its license and collaboration pact with Johnson & Johnson's Janssen Pharmaceuticals Inc. on hepatitis C.

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence

Thursday's downgrade is in part based on a lack of confidence in Achillion's CH-4471 to compete with Alexion Pharmaceuticals' Soliris treatment.

These Two Biotech Stocks Are Going Berserk on Wednesday

These Two Biotech Stocks Are Going Berserk on Wednesday

And then there is Mylan.

Achillion To Host Second Quarter 2017 Results Conference Call On August 8, 2017

Achillion To Host Second Quarter 2017 Results Conference Call On August 8, 2017

- Conference call and live webcast will begin at 4:05 p.m. ET on August 8, 2017 -

March 2018 Options Now Available For Achillion Pharmaceuticals (ACHN)

Investors in Achillion Pharmaceuticals Inc. saw new options begin trading today, for the March 2018 expiration.

Interesting ACHN Put And Call Options For July 21st

Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the July 21st expiration.

Achillion Reports First Quarter 2017 Financial Results And Provides Update On Clinical Programs

Robust balance sheet to support planned Phase 2 clinical development program for ACH-4471, Achillion's first small molecule factor D inhibitor, for the potential treatment of PNH and C3G

Interesting ACHN Put And Call Options For December 15th

Investors in Achillion Pharmaceuticals Inc. saw new options begin trading this week, for the December 15th expiration.

Achillion Announces Additional Phase 2 Results Including 100% SVR24 For Genotype 1 HCV After 6-Weeks Of Once Daily JNJ-4178

Ongoing Janssen global Phase 2 program with JNJ-4178, (odalasvir, AL-335, and simeprevir) focused on treatment durations of six and eight weeks for HCV genotype 1, 2, 4, 5, and 6 patients

If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss

If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss

Here's how to potentially rake in some fat profits off a number of hot breakout setups.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGNC, BBGI, BRID, IIJI, PERY Downgrades: ACHN, ALLY, FPO, FSS, SF, TTMI, VISI Initiations: TKAT Read on to get TheStreet Quant Ratings' detailed report:

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Will Insiders Be Tempted To Buy More ACHN At The New 52-Week Low?

In trading on Friday, shares of Achillion Pharmaceuticals Inc. touched a new 52-week low of $3.75/share.

4 Biotech Stocks on the Move

4 Biotech Stocks on the Move

These four biotech stocks have been moving on some interesting news and clinical results.

Biotech Movers: Cempra Flys High On Phase Three Results

Biotech Movers: Cempra Flys High On Phase Three Results

Other movers include Incyte, Achillion and Inovio.

TheStreet Quant Rating: D (Sell)